ATE273279T1 - 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2 - Google Patents

2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2

Info

Publication number
ATE273279T1
ATE273279T1 AT98942432T AT98942432T ATE273279T1 AT E273279 T1 ATE273279 T1 AT E273279T1 AT 98942432 T AT98942432 T AT 98942432T AT 98942432 T AT98942432 T AT 98942432T AT E273279 T1 ATE273279 T1 AT E273279T1
Authority
AT
Austria
Prior art keywords
cyclooxygenase
inhibitors
formula
treatment
mediated diseases
Prior art date
Application number
AT98942432T
Other languages
English (en)
Inventor
Richard Friesen
Daniel Dube
Denis Deschenes
Rejean Fortin
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800688.5A external-priority patent/GB9800688D0/en
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Application granted granted Critical
Publication of ATE273279T1 publication Critical patent/ATE273279T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98942432T 1997-09-12 1998-09-11 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2 ATE273279T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5863097P 1997-09-12 1997-09-12
GBGB9800688.5A GB9800688D0 (en) 1998-01-14 1998-01-14 2,3,5-trisubsitiuted pyridines as inhibitors of cyclooxygenase-2
PCT/CA1998/000862 WO1999014194A1 (en) 1997-09-12 1998-09-11 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2

Publications (1)

Publication Number Publication Date
ATE273279T1 true ATE273279T1 (de) 2004-08-15

Family

ID=26312937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98942432T ATE273279T1 (de) 1997-09-12 1998-09-11 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2

Country Status (8)

Country Link
EP (1) EP1012142B1 (de)
JP (1) JP4290872B2 (de)
AT (1) ATE273279T1 (de)
AU (1) AU741755B2 (de)
CA (1) CA2301742C (de)
DE (1) DE69825603T2 (de)
ES (1) ES2226167T3 (de)
WO (1) WO1999014194A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525053B1 (en) 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2001045703A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
JP2004510705A (ja) 2000-07-20 2004-04-08 ラウラス　エイエス 方法
CA2432642A1 (en) 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
JP5208510B2 (ja) 2004-11-23 2013-06-12 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (de) 2005-10-06 2008-07-02 Astra Zeneca AB Neue verbindungen
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
ES2594409T3 (es) 2011-02-23 2016-12-20 Lupin Limited Derivados de heteroarilo como moduladores del nAChR á7
WO2013005153A1 (en) 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
IN2014MN01756A (de) 2012-03-06 2015-07-03 Lupin Ltd
US20150299178A1 (en) 2012-11-12 2015-10-22 Lupin Limited Thiazole Derivatives as Alpha 7 NACHR Modulators
WO2014111839A1 (en) 2013-01-16 2014-07-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
WO2014203150A1 (en) 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
CN112694497A (zh) * 2020-12-25 2021-04-23 蚌埠中实化学技术有限公司 一种4-异丙基磺酰基苯硼酸的制备方法
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation

Also Published As

Publication number Publication date
CA2301742C (en) 2004-05-18
EP1012142A1 (de) 2000-06-28
DE69825603T2 (de) 2005-07-28
JP2001516742A (ja) 2001-10-02
ES2226167T3 (es) 2005-03-16
EP1012142B1 (de) 2004-08-11
WO1999014194A1 (en) 1999-03-25
AU741755B2 (en) 2001-12-06
DE69825603D1 (de) 2004-09-16
AU9058798A (en) 1999-04-05
CA2301742A1 (en) 1999-03-25
JP4290872B2 (ja) 2009-07-08

Similar Documents

Publication Publication Date Title
ATE273279T1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
YU59198A (sh) Supstituisani piridini kao selektivni inhibitori ciklooksigenaze-2
DE69529690T2 (de) Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
DK0778834T3 (da) Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2
ES2165969T3 (es) Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios.
DE69825154D1 (de) Pyridazinone als inhibitoren von cyclooxygenase-2
DK0828724T3 (da) 5-oxygenerede diaryl-2-(5H)-furanoner som COX-2-inhibitorer
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
PL326203A1 (en) (methylsulphonyl)phenyl-2-(5)-furanones as cox-2 inhibitors
MX9604378A (es) Amidas de acido quinolin-2-carboxilico sustituidas, su preparacion y su empleo como medicamentos, asi como productos intermedios.
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
DE69829861D1 (de) 2-aminopyridine als inhibitoren von cyclooxygenase-2
CA2252401A1 (en) Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties